Podcast

Comparing micro-bypass implant + phaco vs phaco in POAG

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|AAO

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.



During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

See more AAO coverage

Related Videos
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Glaukos announces several positive clinical updates for its iDose platform
January 20th 2025

Glaukos announces several positive clinical updates for its iDose platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Bausch + Lomb, Glaucoma Research Foundation partner for second annual Faces of Glaucoma campaign
January 8th 2025

Bausch + Lomb, Glaucoma Research Foundation partner for second annual Faces of Glaucoma campaign

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study validates long-term efficacy of MicroPulse TLT for glaucoma management
Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment
December 13th 2024

Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment

© 2025 MJH Life Sciences

All rights reserved.